Essex Bio-Technology (HKSE:01061) ROCE % : 19.32% (As of Jun. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Essex Bio-Technology's annualized ROCE % for the quarter that ended in Jun. 2024 was 19.32%.

Essex Bio-Technology ROCE % Historical Data

The historical data trend for Essex Bio-Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Essex Bio-Technology ROCE % Chart

Essex Bio-Technology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

26.54

14.91

20.24

12.57

17.14

Essex Bio-Technology Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															15.40	9.66	19.68	13.55	19.32

Essex Bio-Technology ROCE % Calculation

Essex Bio-Technology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	357.227	/	( ( (2712.397 - 560.917)	+	(2827.558 - 810.744) )	/ 2 )
	=	357.227	/	( (2151.48	+	2016.814)	/ 2 )
	=	357.227	/	2084.147
	=	17.14 %

Essex Bio-Technology's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	401.644	/	( ( (2827.558 - 810.744)	+	(2965.806 - 824.204) )	/ 2 )
	=	401.644	/	( ( 2016.814	+	2141.602 )	/ 2 )
	=	401.644	/	2079.208
	=	19.32 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Essex Bio-Technology (HKSE:01061) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Essex Bio-Technology ROCE % Related Terms

Thank you for viewing the detailed overview of Essex Bio-Technology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Essex Bio-Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN

Website

http://www.essexbio.com

Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.

Executives

Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin	2101 Beneficial owner

Essex Bio-Technology Headlines

No Headlines